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Objective: Hepatocellular carcinoma (HCC) is a common cause of cancer mortality. Resection is the best
choice for HCC. Our objective was to evaluate the impact of various factors that affected survival in
patients with resectable HCC.
Materials and methods: Between January 1, 2007 and December 31, 2013, 107 patients with a diagnosis of
HCC who underwent surgery were enrolled retrospectively. The analysis was carried using t tests, the
KaplaneMeier method, and Cox proportional hazard regression model to identify potential confounding
and predicting variables.
Results: The 3-year overall survival rates in patients with surgical margins >1 mm and 1 mmwere 79%
and 59% (p ¼ 0.02), respectively, and those in patients with and without vascular invasion were 57% and
93% (p < 0.001), respectively. Based on multivariate analysis, postoperative pathological vascular invasion
(hazard ratio, 6.25; 95% conﬁdence interval, 2.01e19.37) and surgical margin (hazard ratio, 0.37; 95%
conﬁdence interval, 0.14e0.96) remained independent predictors of an adverse long-term outcome.
Conclusion: Patients with vascular invasion combined with surgical margins 1 mm are at risk of poor
survival and have a worse locoregional control rate. Further studies are warranted to identify the optimal
strategy for the prevention and management of intrahepatic recurrence in order to further improve the
prognosis of HCC after resection.
Copyright © 2014, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Hepatocellular carcinoma (HCC) is one of the most common
causes of cancer mortality in Taiwan. The 5-year survival rate of
individuals is low, and there is an increasing mortality rate [1].
Several modalities, including surgical resection, transcatheter
arterial chemoembolization, arterial infusion chemotherapy,
percutaneous ethanol injection therapy, microwave coagulation
therapy, radiotherapy, and liver transplantation, have been usedncology, Buddhist Dalin Tzu
hiayi, Taiwan. Tel.: þ886 5
. Hung).
elief Tzu Chi Foundation. Publisheto treat HCC [2e4]. The traditional approach to the treatment of
HCC has been hepatic resection, because resection can be per-
formed without delay and it is associated with low mortality
[4]. However, the rate of intrahepatic recurrence has been
high [5].
The main causes of late death after hepatectomy are related to
intrahepatic cancer recurrence or progressive liver insufﬁciency
due to cirrhosis. Various factors, such as patient age, size and
number of tumors, presence of a tumor capsule, vascular invasion,
histological grading, pathological stage, and surgical margins, have
all been demonstrated to inﬂuence recurrence postoperatively
[6,7]. Importantly, improved survival after hepatectomy for HCC
has been attributedmainly to the prevention of recurrence. The aim
of this study was to evaluate the results after surgical treatment of
107 patients with HCC in the same institution; a range of prognostic
factors were also analyzed.d by Elsevier Taiwan LLC. All rights reserved.
Table 1
Characteristics of 107 patients with hepatocellular carcinoma.
Variable Number of patients %
Age (y)
<60 53 49.5
60 54 50.5
Sex
Male 82 76.6
Female 25 23.4
pT
pT 1e2 91 85.0
pT 3e4 16 15.0
Vascular permeation
No 52 48.6
Yes 55 51.4
Tumor size
<45 68 63.6
45 39 36.4
Surgical margin
(þ) 10 9.3
() 97 90.7
1(mm) 23 21.5
>1 84 78.5
Stage
I 39 36.4
II 51 47.7
III 17 15.9
BCLC stage
0 25 23.4
A 47 43.9
B 26 24.3
C 9 8.4
HBV carrier 48 44.8
HCV carrier 38 35.5
Non-HBV and non-HCV carriers 14 13.1
Concurrent with HBV and HCV carriers 7 6.5%
BCLC ¼ Barcelona-clinic liver cancer; HBV ¼ hepatitis B virus; HCV ¼ hepatitis C
virus; pT ¼ pathological T.
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2.1. Patients
Between January 1, 2007 and December 31, 2013, 107 patients
with the diagnosis of HCC, who underwent partial hepatectomy
with complete gross resection of the disease, were enrolled
retrospectively. The study was approved by the Institutional
Review Boards of the respective institutions [DTCRD101(2)-I-18].
All patients were evaluated based on a baseline history and
physical examination, serum laboratory tests, and a computed
tomography or magnetic resonance imaging scan of the abdomen
and pelvis.
2.2. Follow-up
Postoperatively, patients were followed up by physical exami-
nations, serial computed tomography scans or ultrasonography,
and alpha-fetoprotein levels at 3e6-month intervals for the 1st year
and every 6 months thereafter. All patients in this analysis had a
minimum of a 6-month follow-up examination. Recurrence of HCC
was identiﬁed by new lesions on imaging, with an appearance
typical of HCC, or by a rising alpha-fetoprotein level. Lesions that
were not typical of HCC were conﬁrmed by biopsy. Pathological
specimens were reviewed for the following tumor characteristics:
number and size of tumors, tumor grade, vascular invasion, and
microscopic margins. A margin of >1 mm was considered a nega-
tive margin, whereas a margin between 0 mm and 1 mm was
considered a close margin. A positive margin indicated histological
involvement. Pathological vascular invasion was deﬁned as
encroachment into blood vessels by a pathological process. Mac-
rovascular involvement was deﬁned as histological involvement of
the lobar or segmental branches of portal or hepatic veins, or gross
invasion of the right or left main branches of the portal or hepatic
veins.
2.3. Analysis
Patient demographics, tumor, operative treatment, and treat-
ment characteristics were evaluated. The following variables were
analyzed: age, sex, ChildePugh classiﬁcation of cirrhosis, alpha-
fetoprotein level, hepatitis serological condition, and extent of
resection. Stage was determined by the seventh American Joint
Commission on Cancer (AJCC) system.
Comparisons between groups were performed using the Chi-
square test for categorical variables and t test for continuous vari-
ables. Time to recurrence (disease-free survival) and time to death
were determined by KaplaneMeier analysis, and the results for
subgroups of patients were compared with a log-rank test (SPSS
software version 17.0; SPSS Inc., Chicago, IL, USA). All variables that
appeared to be associated signiﬁcantly with survival (p < 0.05)
were entered into a Cox proportional hazards model to test for
signiﬁcant effects and adjustment for multiple factors simulta-
neously. A probability value of <0.05 was considered to be statis-
tically signiﬁcant.
3. Results
Demographics of this cohort are shown in Table 1. Of the pa-
tients, 49.5% were <60 years of age and 76.7% were male. Most
patients had Barcelona-clinic liver cancer (BCLC) stages 0 and A
(67%), based on clinical and laboratory evaluation. Nine patients
were classiﬁed as BCLC stage C. Most of the tumors were AJCC T-
stage 1/2 (85%) and Stage I/II (84%). Twenty-three patients (21.5%)
had close (0.1 cm) margins, 10 of whom had positive margins(9.3%). Pathological vascular invasionwas common and found in 55
patients (51%). In 39 patients (63%), the tumors were larger than
4.5 cm in size. Fifty-seven patients (53.3%) had liver cirrhosis. Forty-
eight patients (44.8%) and 38 patients (35.5%) were hepatitis B virus
(HBV) and hepatitis C virus (HCV) carriers, respectively. The num-
ber of non-HBV and non-HCV HCC patients was 14 (13.1%). Seven
patients (6.5%) had concurrent HBV and HCV infections.
The median follow-up time was 22.3 months. The 3-year overall
survival (OS), disease-free survival, disease-speciﬁc survival,
locoregional recurrence-free, and distant metastasis-free rates
were 68%, 35%, 73%, 36%, and 93%, respectively. The 3-year OS rates
for Stages I, II, and III were 91%, 71%, and 49%, respectively
(p ¼ 0.001). The 3-year OS rates for surgical margins of >1 mm and
1mmwere 79% and 59%, respectively (p¼ 0.02; Fig.1A); however,
no differences were observed in these rates for surgical margins of
>2mm and2mm (p¼ 0.1; Fig. 1B). The 3-year OS rates in patients
with or without vascular invasion were 57% and 93%, respectively
(p < 0.001). Moreover, pathological T (pT) stage and cirrhosis status
also inﬂuenced the OS rates (Table 2).
The median time to recurrence was 8.8 months (range, 2e43
months); 44 patients (41%) had recurrent cancer. Among these
patients, initial tumor recurrence was conﬁned to the original
segment of the liver in 12 patients (11%) or to different segments of
the liver in 36 patients (34%). Two patients had both distant lung
and brain failure.
Based on univariate analysis, the factors with the greatest in-
ﬂuence on the OS rate were tumor diameter, vascular permeation,
stage, margin, sex, and BCLC status. Stage, pT stage, BCLC status, and
vascular invasion also affected locoregional recurrence signiﬁ-
cantly, whereas a positive surgical margin did not affect the time to
recurrence (p ¼ 0.28).
Fig. 1. Three-year overall survival curve for all hepatocellular carcinoma patients ac-
cording to surgical margins of (A) 1 mm or >1 mm and (B) 2 mm or >2 mm
(N ¼ 107).
Table 2
Three-year clinical outcomes according to prognostic factors.
Factor Overall
survival (%)
p Disease free
survival (%)
p Diseas
surviva
Age (y)
<60/60 75.2/75.2 0.35 56.7/36.2 0.50 78.4/7
Sex
Male/female 70.1/90.2 0.04* 44.4/57.4 0.34 72.1/9
pT
pT 1e2/pT 3e4 79.6/46.4 <0.001* 51.9/11.2 <0.001* 81.5/4
Vascular permeation
No/yes 93.1/56.6 <0.001* 60.0/31.4 <0.001* 95.0/5
Tumor size
<45/45 80.4/64.9 0.04* 52.6/32.0 0.04* 82.9/6
Surgical margin
(þ)/(e) 50.0/77.2 0.01* 30.0/46.6 0.16 50.0/7
1/>1 (mm) 58.9/78.8 0.02* 37.1/46.6 0.14 61.6/7
2/>2 (mm) 65.9/78.5 0.10 33.7/50.7 0.17 67.9/7
Stage
I/II/III 90.6/71.3/48.9 0.001* 63.0/43.4/12.4 <0.001* 93.0/7
BCLC stage
0/A/B/C 78.4/85.9/66.0/51.9 0.01* 53.5/47.5/44.7/0.0 <0.001* 78.4/8
*p < 0.05.
BCLC ¼ Barcelona-clinic liver cancer; pT ¼ pathological T.
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included in the multivariate Cox model (Table 3). Based on multi-
variate analysis, postoperative pathological vascular invasion
(hazard ratio, 6.25; 95% conﬁdence interval, 2.01e19.37) and sur-
gical margins (hazard ratio, 0.37; 95% conﬁdence interval,
0.14e0.96) remained independent predictors of adverse long-term
outcomes. Age, sex, and BCLC stage were found not to affect OS.
4. Discussion
The outcome of hepatic resection for HCC has improved signif-
icantly because of superior surgical techniques and improved
perioperative care. Partial hepatectomy for select patients with HCC
can now be performed with low operative morbidity and mortality
[8]. However, long-term survival is still unsatisfactory due to the
high incidence of recurrence, especially in the liver remnant [9].
Intrahepatic recurrence after resection of HCC can be the result of
intrahepatic metastasis or multicentric occurrence of a new tumor
in the liver remnant, or both. A recurrence rate as high as 74% was
reported at 5 years after hepatic resection [10]. In addition, intra-
hepatic recurrence occurred in 43% at a median follow-up of 24
months [9]. Another study also revealed that recurrent disease
accounted for 60% of late deaths after partial hepatectomy [11]. In
the current study, 41% of patients had recurrent cancer in the
original segment (11%) or in multiple segments of the liver (34%),
which also suggested that the majority of the recurrent tumors
after hepatectomy arose from intrahepatic metastasis.
Chronic active hepatitis and cirrhosis have been reported to be
signiﬁcant risk factors for intrahepatic recurrence of HCC [12].
Kosuge et al [13] reported an unfavorable effect of liver disease,
particularly cirrhosis, which became more pronounced over time.
Moreover, the presence of moderate-to-severe ﬁbrosis/cirrhosis
has been found to be the most important predictor of death [12]. In
our study, there was a trend that liver cirrhosis may inﬂuence the
control rate (p ¼ 0.07). The possible reasons for the lack of a sta-
tistically signiﬁcant difference could be the limited case number
and shorter follow-up time.
Vascular invasion is a known prognostic factor after resection of
HCC [6]. In a study of 164 patients who underwent liver resection
for HCC, multivariate analysis showed that only tumor size >5 cm
and vascular invasionwere signiﬁcant predictors of recurrence [14].e speciﬁc
l (%)
p Locoregional
recurrence
survival (%)
p Distant recurrence
survival (%)
p
5.2 0.76 66.2/61.7 0.72 93.6/91.5 0.73
0.2 0.07 61.1/68.6 0.94 94.4/87.2 0.29
6.4 <0.001* 65.8/43.5 0.001* 94.3/75.0 0.13
7.6 <0.001* 77.6/46.7 0.01* 100.0/84.1 0.004*
4.9 0.01* 65.9/57.9 0.07 95.3/87.0 0.20
8.9 0.005* 53.3/62.0 0.62 100.0/92.0 0.49
9.9 0.02* 75.0/60.4 0.46 88.7/93.4 0.41
9.7 0.08 73.3/59.0 0.50 92.9/92.5 0.96
2.7/48.9 <0.001* 72.1/61.0/44.6 0.004* 100.0/89.6/75.8 0.07
7.9/68.7/51.9 0.005* 85.2/56.6/57.2/0.0 <0.001* 91.7/97.8/91.7/40.0 0.03*
Table 3
Prognostic factors affecting clinical outcomes in multivariate analysis.
Factor B HR 95% CI p
Age (y) 0.02 0.97 (0.93e1.01) 0.25
Sex
Male (reference) 1 0.12
Female 1.19 0.30 (0.06e1.37)
Vascular permeation
No (reference) 1 0.002*
Yes 1.83 6.25 (2.01e19.37)
Surgical margin
1 (mm) (reference) 1 0.04*
>1 0.98 0.37 (0.14e0.96)
BCLC stage
0 (reference) 1 0.59
A 0.04 1.04 (0.32e3.33)
B 0.62 1.87 (0.63e5.47)
C 0.56 1.75 (0.43e7.07)
*p < 0.05.
CI ¼ conﬁdence interval; HR ¼ hazard ratio.
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had a signiﬁcantly shorter median survival compared with those
without evidence of vascular invasion. In the current study, we had
similar results. When patients with and without vascular invasion
proved by pathology were compared, the 3-year OS was 57% and
93% (p < 0.001), respectively.Fig. 2. All hepatocellular carcinoma patients, according to surgical margin concurrent
with pathological vascular invasion. (A) The 3-year actuarial overall survival curve and
(B) the 3-year actuarial locoregional control curve (N ¼ 107).In previous reports, patients, tumor characteristics, and surgical
variables have been found to inﬂuence recurrence after surgical
resection for HCC. Controversy persists regarding what is an
adequate surgical margin for recurrence. In our study, close surgical
margins (1 mm) were associated with poor survival compared to
margins of >1 mm (p ¼ 0.02; Fig. 1A and B). Shah and colleagues
[16] noted that vascular invasion and microscopic margins had
positive predictive values of 77% and 73%, respectively. However,
limited studies have mentioned an association between concurrent
surgical margins and microscopic vascular invasion. We analyzed
these patients and showed that patients with both factors have a
poor OS (p < 0.001) and a trend toward locoregional recurrence
(p ¼ 0.06; Fig. 2A and B). Although we had limitations in terms of
case numbers and short follow-up times, the results are signiﬁcant.
Given the robustness of the evidence and statistical analysis in this
study, these limitations are unlikely to have compromised our
results.
The improved survival that has begun to be seen recently after
hepatectomy for HCC is attributable mainly to the prevention of
recurrence. In one study, out of 164 patients who underwent liver
resections for HCC with a median follow-up of 26 months, 74% had
isolated recurrence in the liver; based on this, the authors suggest a
role for adjuvant therapy after hepatectomy [14]. Aggressive
treatment with a multimodality strategy has been suggested for
patients with intrahepatic recurrence after curative resection
because patients’ survival was found to be improved by additional
therapy. Shah et al [6] revealed that among 98 recurrence patients,
53 (54%) who underwent additional therapy (ablation, 31 patients;
re-resection, 11 patients; transarterial chemoembolization, 8 pa-
tients; liver transplantation, 3 patients) showed improvement in
survival. A number of adjuvant therapies are available [17e20].
Further randomized trials are needed to compare these therapies
and assess fully their beneﬁts to patients at high risk of intrahepatic
metastasis.5. Conclusion
In conclusion, this study demonstrated that TNM stage, BCLC
stage, tumor size, cirrhosis, vascular invasion, and surgical margin
are associated with survival after resection of HCC. Patients with
both pathological vascular invasion and a surgical margin of <1mm
are at a risk for poorer survival and worse locoregional control.
These ﬁndings emphasize the need for effective adjuvant therapy in
HCC that has speciﬁc risk factors. Further studies are warranted to
identify the optimal strategy, or strategies needed to prevent and
manage intrahepatic recurrences; such management ought to
further improve the prognosis of HCC and have a signiﬁcant impact
on the quality of life after curative resection.Acknowledgments
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